Loading
A phase 1/2 trial of AST-3424 run by OBI Pharma, Inc, terminated.
A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT03592264 by OBI Pharma, Inc, with 68 participants enrolled, started 2018-07-02. Conditions recorded: Solid Tumor and Pancreatic Adenocarcinoma. Interventions recorded: OBI-3424.
Shares OBI Pharma, Zhejiang Hisun Pharmaceutical, Ascentawits Pharmaceuticals, AST-3424 and the tag pipeline.
Shares Ascentawits Pharmaceuticals, AST-3424 and the tag pipeline.
Shares Ascentawits Pharmaceuticals, Metastatic cancer (cancer that has spread), Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Ascentawits Pharmaceuticals, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares OBI Pharma and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pancreatic ductal adenocarcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/